Xenetic Biosciences (NASDAQ:XBIO – Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.48), Zacks reports. Xenetic Biosciences had a negative net margin of 161.63% and a negative return on equity of 49.51%.
Xenetic Biosciences Stock Down 5.7 %
Shares of Xenetic Biosciences stock traded down $0.21 on Tuesday, hitting $3.46. The stock had a trading volume of 13,751 shares, compared to its average volume of 12,669. Xenetic Biosciences has a one year low of $2.78 and a one year high of $5.20. The stock has a market cap of $5.34 million, a price-to-earnings ratio of -1.30 and a beta of 2.17. The stock’s 50-day simple moving average is $4.03 and its two-hundred day simple moving average is $4.01.
Wall Street Analyst Weigh In
Separately, HC Wainwright reiterated a “neutral” rating on shares of Xenetic Biosciences in a research report on Thursday, December 5th.
About Xenetic Biosciences
Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.
Featured Stories
- Five stocks we like better than Xenetic Biosciences
- How to Calculate Return on Investment (ROI)
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- What is Insider Trading? What You Can Learn from Insider Trading
- 3 Must-Own Stocks to Build Wealth This Decade
- Find and Profitably Trade Stocks at 52-Week Lows
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for Xenetic Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.